Efficacy and Safety of Neoadjuvant Monoimmunotherapy With PD-1 Inhibitor for dMMR/MSI⁃H Locally Advanced Colorectal Cancer: A Single-Center Real-World Study
出版年份 2022 全文链接
标题
Efficacy and Safety of Neoadjuvant Monoimmunotherapy With PD-1 Inhibitor for dMMR/MSI⁃H Locally Advanced Colorectal Cancer: A Single-Center Real-World Study
作者
关键词
-
出版物
Frontiers in Immunology
Volume 13, Issue -, Pages -
出版商
Frontiers Media SA
发表日期
2022-07-25
DOI
10.3389/fimmu.2022.913483
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
- (2021) Hyuna Sung et al. CA-A CANCER JOURNAL FOR CLINICIANS
- DNA mismatch repair proteins: scientific update and practical guide
- (2021) Adrian C Bateman JOURNAL OF CLINICAL PATHOLOGY
- Colon Cancer, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology
- (2021) Al B. Benson et al. Journal of the National Comprehensive Cancer Network
- Defining the current role of immune checkpoint inhibitors in the treatment of mismatch repair-deficient/microsatellite stability-high colorectal cancer and shedding light on future approaches
- (2021) Elaine Tan et al. Expert Review of Gastroenterology & Hepatology
- Health-related quality of life in patients with microsatellite instability-high or mismatch repair deficient metastatic colorectal cancer treated with first-line pembrolizumab versus chemotherapy (KEYNOTE-177): an open-label, randomised, phase 3 trial
- (2021) Thierry Andre et al. LANCET ONCOLOGY
- First-Line Nivolumab Plus Low-Dose Ipilimumab for Microsatellite Instability-High/Mismatch Repair-Deficient Metastatic Colorectal Cancer: The Phase II CheckMate 142 Study
- (2021) Heinz-Josef Lenz et al. JOURNAL OF CLINICAL ONCOLOGY
- Neoadjuvant PD-1 blockade with toripalimab, with or without celecoxib, in mismatch repair-deficient or microsatellite instability-high, locally advanced, colorectal cancer (PICC): a single-centre, parallel-group, non-comparative, randomised, phase 2 trial
- (2021) Huabin Hu et al. Lancet Gastroenterology & Hepatology
- Mismatch Repair Deficient Rectal Cancer and Resistance to Neoadjuvant Chemotherapy
- (2020) Andrea Cercek et al. CLINICAL CANCER RESEARCH
- Neoadjuvant checkpoint blockade for cancer immunotherapy
- (2020) Suzanne L. Topalian et al. SCIENCE
- PD-1 blockade in neoadjuvant setting of DNA mismatch repair-deficient/microsatellite instability-high colorectal cancer
- (2020) Ding-Xin Liu et al. OncoImmunology
- Immunotherapy, Inflammation and Colorectal Cancer
- (2020) Charles Robert Lichtenstern et al. Cells
- Neoadjuvant immunotherapy leads to pathological responses in MMR-proficient and MMR-deficient early-stage colon cancers
- (2020) Myriam Chalabi et al. NATURE MEDICINE
- Survival of patients with deficient mismatch repair metastatic colorectal cancer in the pre-immunotherapy era
- (2020) G. Emerens Wensink et al. BRITISH JOURNAL OF CANCER
- Pembrolizumab in Microsatellite-Instability–High Advanced Colorectal Cancer
- (2020) Thierry André et al. NEW ENGLAND JOURNAL OF MEDICINE
- Clinicopathological features of mismatch repair protein expression patterns in colorectal cancer
- (2020) Chung-Ta Lee et al. PATHOLOGY RESEARCH AND PRACTICE
- Mismatch Repair System Deficiency Is Associated With Response to Neoadjuvant Chemoradiation in Locally Advanced Rectal Cancer
- (2019) Nicolas Meillan et al. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS
- Complete response in patients with locally advanced rectal cancer after neoadjuvant treatment with nivolumab
- (2019) Jianwei Zhang et al. OncoImmunology
- New NCCN Guidelines: Recognition and Management of Immunotherapy-Related Toxicity
- (2018) John A. Thompson Journal of the National Comprehensive Cancer Network
- Assessment of Tumor Sequencing as a Replacement for Lynch Syndrome Screening and Current Molecular Tests for Patients With Colorectal Cancer
- (2018) Heather Hampel et al. JAMA Oncology
- Association of Primary Resistance to Immune Checkpoint Inhibitors in Metastatic Colorectal Cancer With Misdiagnosis of Microsatellite Instability or Mismatch Repair Deficiency Status
- (2018) Romain Cohen et al. JAMA Oncology
- Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 study
- (2017) Michael J Overman et al. LANCET ONCOLOGY
- PD-1 inhibitor gastroenterocolitis: case series and appraisal of ‘immunomodulatory gastroenterocolitis’
- (2016) Raul S Gonzalez et al. HISTOPATHOLOGY
- DNA Mismatch Repair Deficiency in Rectal Cancer: Benchmarking Its Impact on Prognosis, Neoadjuvant Response Prediction, and Clinical Cancer Genetics
- (2016) Nicole de Rosa et al. JOURNAL OF CLINICAL ONCOLOGY
- Efficacy of Adjuvant Chemotherapy in Colon Cancer With Microsatellite Instability: A Large Multicenter AGEO Study
- (2016) David Tougeron et al. JNCI-Journal of the National Cancer Institute
- Genetic/Familial High-Risk Assessment: Colorectal Version 1.2016, NCCN Clinical Practice Guidelines in Oncology
- (2016) Dawn Provenzale et al. Journal of the National Comprehensive Cancer Network
- Efficacy of Adjuvant Chemotherapy in Colon Cancer With Microsatellite Instability: A Large Multicenter AGEO Study
- (2016) David Tougeron et al. JNCI-Journal of the National Cancer Institute
- PD-1 Blockade in Tumors with Mismatch-Repair Deficiency
- (2015) Dung T. Le et al. NEW ENGLAND JOURNAL OF MEDICINE
- Feasibility of preoperative chemotherapy for locally advanced, operable colon cancer: the pilot phase of a randomised controlled trial
- (2012) FOxTROT Collaborative Group LANCET ONCOLOGY
- Defective Mismatch Repair As a Predictive Marker for Lack of Efficacy of Fluorouracil-Based Adjuvant Therapy in Colon Cancer
- (2010) Daniel J. Sargent et al. JOURNAL OF CLINICAL ONCOLOGY
- Microsatellite instability in colorectal cancer—the stable evidence
- (2010) Eduardo Vilar et al. Nature Reviews Clinical Oncology
- New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
- (2008) E.A. Eisenhauer et al. EUROPEAN JOURNAL OF CANCER
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started